Placebo for AMG 890
Sponsors
Amgen Inc.
Conditions
Cardiovascular DiseaseCardiovascular disease (atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein (a))
Phase 3
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Active, not recruitingCTIS2022-501608-85-00
Start: 2023-05-09Target: 3511Updated: 2025-12-11
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
Not yet recruitingCTIS2025-520554-11-00
Target: 3800Updated: 2025-09-29
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Not yet recruitingCTIS2025-521117-88-00
Target: 178Updated: 2026-01-12